Gufic Biosciences Limited (GUFICBIO.BO)
INR 317.25
(2.11%)
INR 317.25
(2.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.32 Billion INR | 9.52% |
| 2022 | 1.17 Billion INR | -9.11% |
| 2021 | 1.29 Billion INR | 89.05% |
| 2020 | 684.66 Million INR | 70.8% |
| 2019 | 400.86 Million INR | -3.95% |
| 2018 | 417.34 Million INR | 20.32% |
| 2017 | 346.86 Million INR | 99.35% |
| 2016 | 173.99 Million INR | 60.65% |
| 2015 | 108.3 Million INR | 78.59% |
| 2014 | 60.64 Million INR | 5.28% |
| 2013 | 57.6 Million INR | 15.89% |
| 2012 | 49.7 Million INR | 89.88% |
| 2011 | 26.17 Million INR | 18.01% |
| 2010 | 22.18 Million INR | 30.98% |
| 2009 | 16.93 Million INR | -1.4% |
| 2008 | 17.17 Million INR | 10.02% |
| 2007 | 15.61 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 314.74 Million INR | -2.6% |
| 2023 Q3 | 327.36 Million INR | -6.66% |
| 2023 Q4 | 323.13 Million INR | -1.29% |
| 2023 FY | 1.28 Billion INR | 9.52% |
| 2023 Q2 | 350.72 Million INR | 12.26% |
| 2023 Q1 | 312.4 Million INR | 19.1% |
| 2022 FY | 1.17 Billion INR | -9.11% |
| 2022 Q3 | 286.5 Million INR | 2.15% |
| 2022 Q4 | 262.3 Million INR | -8.45% |
| 2022 Q1 | 288.13 Million INR | 5.96% |
| 2022 Q2 | 280.48 Million INR | -2.66% |
| 2021 Q3 | 282.33 Million INR | -10.75% |
| 2021 Q4 | 271.92 Million INR | -3.69% |
| 2021 Q1 | 415.22 Million INR | 115.53% |
| 2021 FY | 1.29 Billion INR | 89.05% |
| 2021 Q2 | 316.32 Million INR | -23.82% |
| 2020 FY | 684.66 Million INR | 70.8% |
| 2020 Q4 | 192.64 Million INR | -20.5% |
| 2020 Q3 | 242.31 Million INR | -8.94% |
| 2020 Q2 | 266.11 Million INR | 4479.5% |
| 2020 Q1 | 5.81 Million INR | -93.04% |
| 2019 Q4 | 83.51 Million INR | -35.12% |
| 2019 Q3 | 128.72 Million INR | 40.61% |
| 2019 Q2 | 91.54 Million INR | -23.45% |
| 2019 Q1 | 119.58 Million INR | -14.25% |
| 2019 FY | 400.86 Million INR | -3.95% |
| 2018 Q3 | 111.37 Million INR | -7.08% |
| 2018 FY | 417.34 Million INR | 20.32% |
| 2018 Q4 | 139.46 Million INR | 25.22% |
| 2018 Q2 | 119.86 Million INR | -15.39% |
| 2018 Q1 | 141.67 Million INR | 53.78% |
| 2017 Q1 | 58.79 Million INR | 11.53% |
| 2017 FY | 346.86 Million INR | 99.35% |
| 2017 Q3 | 96.95 Million INR | 30.07% |
| 2017 Q4 | 92.12 Million INR | -4.98% |
| 2017 Q2 | 74.54 Million INR | 26.77% |
| 2016 FY | 173.99 Million INR | 60.65% |
| 2016 Q2 | 42.48 Million INR | 1.79% |
| 2016 Q1 | 41.73 Million INR | 14.05% |
| 2016 Q4 | 52.72 Million INR | 19.77% |
| 2016 Q3 | 44.02 Million INR | 3.63% |
| 2015 Q1 | 16.1 Million INR | 199.26% |
| 2015 Q2 | 26.06 Million INR | 61.92% |
| 2015 Q3 | 33.15 Million INR | 27.17% |
| 2015 FY | 108.3 Million INR | 78.59% |
| 2015 Q4 | 36.59 Million INR | 10.37% |
| 2014 Q3 | 13.56 Million INR | -31.77% |
| 2014 Q4 | 5.38 Million INR | -60.35% |
| 2014 Q2 | 19.88 Million INR | -8.82% |
| 2014 Q1 | 21.81 Million INR | 48.06% |
| 2014 FY | 60.64 Million INR | 5.28% |
| 2013 Q2 | 15.05 Million INR | -76.0% |
| 2013 Q4 | 14.73 Million INR | -5.31% |
| 2013 FY | 57.6 Million INR | 15.89% |
| 2013 Q3 | 15.55 Million INR | 3.33% |
| 2013 Q1 | 62.73 Million INR | 556.26% |
| 2012 FY | 49.7 Million INR | 89.88% |
| 2012 Q1 | 13.48 Million INR | 258.26% |
| 2012 Q4 | 9.55 Million INR | -26.75% |
| 2012 Q3 | 13.05 Million INR | -4.13% |
| 2012 Q2 | 13.61 Million INR | 0.94% |
| 2011 Q3 | 6.28 Million INR | 0.0% |
| 2011 FY | 26.17 Million INR | 18.01% |
| 2011 Q4 | 3.76 Million INR | -40.13% |
| 2010 FY | 22.18 Million INR | 30.98% |
| 2009 FY | 16.93 Million INR | -1.4% |
| 2008 FY | 17.17 Million INR | 10.02% |
| 2007 FY | 15.61 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 76.904% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 96.849% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 85.189% |
| Granules India Limited | 6.81 Billion INR | 80.49% |
| Indoco Remedies Limited | 1.29 Billion INR | -2.89% |
| Achyut Healthcare Limited | 4.43 Million INR | -29866.426% |
| Ajanta Pharma Limited | 19.67 Billion INR | 93.241% |
| Alkem Laboratories Limited | 19.46 Billion INR | 93.167% |
| Alpa Laboratories Limited | 184.49 Million INR | -620.83% |
| Brooks Laboratories Limited | 14.44 Million INR | -9109.903% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 22.567% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -8.035% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 98.036% |
| Eris Lifesciences Limited | 5.18 Billion INR | 74.335% |
| FDC Limited | 2.98 Billion INR | 55.465% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 79.547% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 69.915% |
| Ipca Laboratories Limited | 7.98 Billion INR | 83.336% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -161.726% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 975.188% |
| Lasa Supergenerics Limited | -458 Million INR | 390.37% |
| Laurus Labs Limited | 3.94 Billion INR | 66.319% |
| Lupin Limited | 28.04 Billion INR | 95.258% |
| Mankind Pharma Limited | 21.51 Billion INR | 93.82% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -1225.932% |
| Megasoft Limited | -121.1 Million INR | 1198.155% |
| NATCO Pharma Limited | 25.96 Billion INR | 94.877% |
| Piramal Pharma Limited | 4.55 Billion INR | 70.815% |
| RPG Life Sciences Limited | 2.29 Billion INR | 41.984% |
| Sigachi Industries Limited | 1.47 Billion INR | 9.769% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.725% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 71.137% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -433.563% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -133.434% |
| Windlas Biotech Limited | 1.29 Billion INR | -2.388% |
| ZIM Laboratories Limited | 253.82 Million INR | -423.939% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 96.915% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 132.318% |
| Divi's Laboratories Limited | 33.08 Billion INR | 95.98% |
| Hester Biosciences Limited | 364.81 Million INR | -264.549% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 52.265% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -190.663% |
| Bal Pharma Limited | 233.9 Million INR | -468.559% |
| Strides Pharma Science Limited | 5.22 Billion INR | 74.551% |
| Venus Remedies Limited | 534.65 Million INR | -148.744% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 57.485% |
| Nectar Lifesciences Limited | 923.8 Million INR | -43.96% |
| Shilpa Medicare Limited | 1.36 Billion INR | 2.661% |
| Aarti Drugs Limited | 7.14 Billion INR | 81.397% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 16.714% |
| Suven Life Sciences Limited | -1.22 Billion INR | 208.491% |
| Ind-Swift Limited | 1.22 Billion INR | -8.479% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 90.689% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 134.517% |
| Themis Medicare Limited | 392.58 Million INR | -238.754% |
| Hikal Limited | 32.11 Million INR | -4041.732% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 94.751% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -112.276% |
| Wockhardt Limited | -670 Million INR | 298.494% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 74.371% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -14564.836% |
| Neuland Laboratories Limited | 5.31 Billion INR | 74.993% |
| Morepen Laboratories Limited | 4.17 Billion INR | 68.137% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -539.226% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -4743.434% |